Abiopharma

Innoviva to Participate in Upcoming Investor Conferences

Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid

Lillys oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

Chemours Publishes 2024 Sustainability Report, Showcasing Latest Progress Against Its 2030 Goals

New Form 6-K - Immuron Ltd Filed: 2025-08-26 AccNo: 0001213900-25-080490 Size: 399 KB

New Form 8-K - Shattuck Labs, Inc. Filed: 2025-08-26 AccNo: 0001193125-25-188078 Size: 177 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - PLUS THERAPEUTICS, INC. Filed: 2025-08-26 AccNo: 0001193125-25-188075 Size: 143 KB Item 8.01: Other Events

New Form 8-K - Autonomix Medical, Inc. Filed: 2025-08-26 AccNo: 0001437749-25-027719 Size: 636 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits

Teleflex - Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Shattuck Labs - Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Teleflex to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

New Form S-8 - ORAGENICS INC Filed: 2025-08-26 AccNo: 0001493152-25-012311 Size: 290 KB

Director Bagai Shaun 🟢 acquired 10.0K shares of RenovoRx, Inc. (RNXT) at $0.95 Transaction Date: Aug 22, 2025 | Filing ID: 025459

New Form EFFECT - Profusa, Inc. Filed: 2025-08-25 AccNo: 9999999995-25-002737 Size: 1 KB